Amplia Therapeutics Appoints Christopher Burns as CEO and MD
- Amplia Therapeutics (ATX) appoints Christopher Burns as CEO and Managing Director, effective from December 5
- Dr Burns has more than 30 years of experience in drug discovery and development and has served in multiple executive positions for public and private biotech companies
- He will be taking the reins from John Lambert, who has been Amplia’s CEO and Managing Director since June 2019 and February 2020, respectively
- Dr Burns and Dr Lambert will work together over the coming months to ensure a “seamless transition” of Amplia’s operations
- Shares in Amplia close 1.01 per cent higher at 10 cents per share
